Team discovers new inhibitors of estrogen-dependent breast cancer cells

Jun 16, 2008

Researchers have discovered a new family of agents that inhibit the growth of estrogen-dependent breast cancer cells. The finding, described today at a meeting of the Endocrine Society, has opened an avenue of research into new drugs to combat estrogen-dependent breast cancers.

"This cell-based study is exciting because it suggests these compounds are likely to be effective in tumors that remain dependent on estrogen for growth but are resistant to current therapies," said principal investigator David J. Shapiro, a professor of biochemistry in the School of Molecular and Cellular Biology at the University of Illinois.

Although multiple factors contribute to the development of breast cancer, estrogens play a key role in the growth of many tumors. More than 80 percent of breast cancer tumors in women over age 45 are activated by estrogen by way of a protein called an estrogen receptor. When estrogen binds to the receptor, this "estrogen-receptor complex" latches on to DNA and prompts it to transcribe the RNA blueprints for new proteins that promote cell growth, migration and division.

Current therapies for estrogen-receptor-positive (ER-positive) breast cancers include the use of drugs, such as tamoxifen, that interfere with estrogen's ability to bind to the estrogen receptor. Over time, however, ER-positive breast cancer tumors become resistant to tamoxifen. In some resistant tumors, tamoxifen even begins to act like estrogen and actually stimulates tumor growth.

"Tamoxifen is useful in that it is very effective at blocking recurrence of breast cancer in patients for whom the entire tumor is removed," Shapiro said. "But for patients who still have existing tumors, eventually those tumors will become resistant."

Shapiro's team sought to target other steps in the pathway of estrogen action. Using a technique they developed that can quickly determine whether the target DNA is – or is not – bound by the estrogen-receptor complex, the team was able to screen a long list of potential therapeutic compounds to see if they inhibited the binding of the complex to the DNA. They then tested these agents in ER-positive breast cancer cells.

The team identified several compounds that reduce the binding of estrogen-receptor complex to the regulatory regions of genes that are normally activated by this complex. These agents effectively retarded production of the proteins that promote the growth and proliferation of ER-positive breast cancer cells.

"These small molecules specifically block growth of estrogen-dependent breast cancer cells with little or no effect on other cells," Shapiro said. "This work sets the stage for further development and testing of these inhibitors."

Source: University of Illinois at Urbana-Champaign

Explore further: New drug resistance mechanism has implications for breast, ovarian cancer treatment

add to favorites email to friend print save as pdf

Related Stories

3-D printers to make human body parts? It's happening

Feb 04, 2015

It sounds like something from a science fiction plot: So-called three-dimensional printers are being used to fashion prosthetic arms and hands, jaw bones, spinal-cord implants - and one day perhaps even living human body ...

Twist1: Complex regulator of cell shape and function

Jan 20, 2015

Transcription factor Twist1 is involved in many processes where cells change shape or function. Thereby, Twist1 is crucial for embryonic development, but has also been implicated in cancer progression. However, the precise ...

World's oldest penguin undergoes cancer radiation

Dec 12, 2014

A toddler on Tuesday peered through thick glass as Tess – the world's oldest African penguin, representing an endangered species set to vanish in the child's lifetime – dove into her pool at the Pueblo Zoo. It was the ...

Recommended for you

User comments : 0

Please sign in to add a comment. Registration is free, and takes less than a minute. Read more

Click here to reset your password.
Sign in to get notified via email when new comments are made.